Syntara Limited
Research Syntara Limited (SNT.AX) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerSNT.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyAUD
- Financial periodFY2026
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a | n/a |
| FY2025 | n/a | -AUD 7.92M | -AUD 11.12M | n/a | -0.01 | AUD 15.08M | AUD 84.00K | AUD 16.02M |
| FY2024 | n/a | -AUD 15.14M | -AUD 14.49M | n/a | -0.02 | AUD 3.52M | AUD 233.00K | AUD 4.68M |
| FY2023 | AUD 5.77M | -AUD 11.36M | -AUD 7.42M | 53.1% | -0.02 | AUD 9.23M | AUD 2.04M | AUD 9.56M |
| FY2022 | AUD 7.43M | -AUD 1.94M | -AUD 16.41M | 100.0% | 0 | AUD 8.94M | AUD 4.29M | AUD 10.80M |
About Syntara Limited
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Syntara Limited do?
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer.